Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 7/2015

Open Access 01-07-2015 | Systematic Review

Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis

Authors: M. Volbeda, J. Wetterslev, C. Gluud, J. G. Zijlstra, I. C. C. van der Horst, F. Keus

Published in: Intensive Care Medicine | Issue 7/2015

Login to get access

Abstract

Introduction

Glucocorticosteroids (steroids) are widely used for sepsis patients. However, the potential benefits and harms of both high and low dose steroids remain unclear. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis (TSA) might shed light on this clinically important question.

Methods

A systematic review was conducted according to a published protocol and The Cochrane Handbook methodology including meta-analyses, TSA of randomised clinical trials, and external validity estimation (GRADE). Randomised clinical trials evaluating steroids were included for sepsis patients (systemic inflammatory response syndrome, sepsis, severe sepsis or septic shock) aged >18 years. Cochrane Central Register of Controlled Trials (CENTRAL), PubMed/Medline, Embase, Web of Science and Cinahl were searched until 18 February 2015. No language restrictions were applied. Primary outcomes were mortality at longest follow-up and serious adverse events.

Results

A total of 35 trials randomising 4682 patients were assessed and reviewed in full text. All trials but two had high risk of bias. No statistically significant effect was found for any dose of steroids versus placebo or no intervention on mortality at maximal follow-up [relative risk (RR) 0.89; TSA adjusted confidence interval (CI) 0.74–1.08]. Two trials with low risk of bias also showed no statistically significant difference (random-effects model RR 0.38, 95 % CI 0.06–2.42). Similar results were obtained in subgroups of trials stratified according to high (>500 mg) or low (≤500 mg) dose hydrocortisone (or equivalent) (RR 0.87; TSA-adjusted CI 0.38–1.99; and RR 0.90; TSA-adjusted CI 0.49–1.67, respectively). There were also no statistically significant effects on serious adverse events other than mortality (RR 1.02; TSA-adjusted CI 0.7–1.48). The effects did not vary according to the degree of sepsis. TSA showed that many more randomised patients are needed before definitive conclusions may be drawn.

Conclusion

Evidence to support or negate the use of steroids in any dose in sepsis patients is lacking. The results of ongoing and future well-designed, large randomised clinical trials are needed.
Appendix
Available only for authorised users
Literature
1.
Vincent JL, Sakr Y, Sprung CL et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353PubMedCrossRef
2.
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef
3.
Batzofin BM, Sprung CL, Weiss YG (2011) The use of steroids in the treatment of severe sepsis and septic shock. Best Pract Res Clin Endocrinol Metab 25:735–743PubMedCrossRef
4.
Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, Gajdos P (1998) Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 46:589–597PubMedCentralPubMedCrossRef
5.
Venkatesh B, Cohen J (2011) Adrenocortical (dys)function in septic shock—a sick euadrenal state. Best Pract Res Clin Endocrinol Metab 25:719–733PubMedCrossRef
6.
Annane D, Bellissant E, Bollaert PE et al (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301:2362–2375PubMedCrossRef
7.
Turner R, Bird S, Higgins J (2013) The impact of study size on meta-analyses: examination of underpowered studies in cochrane reviews. PLoS ONE 8(3):e59202PubMedCentralPubMedCrossRef
8.
9.
Pogue JM, Yusuf S (1997) Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 18:580–593 (discussion 661-6)PubMedCrossRef
10.
Pogue J, Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351:47–52PubMedCrossRef
11.
Brok J, Thorlund K, Wetterslev J, Gluud C (2009) Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 38:287–298PubMedCrossRef
12.
Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61:64–75PubMedCrossRef
13.
da Costa BR (2014) Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J 35:3336–3345PubMedCrossRef
14.
Shamseer L (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349:g7647PubMedCrossRef
15.
16.
Keus F, Wetterslev J, Gluud C, van Laarhoven CJ (2010) Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol 10:90PubMedCentralPubMedCrossRef
17.
Singer M, Webb R (eds) (2009) Oxford handbook of critical care, 3rd edn. Oxford University Press, Oxford, p 329
18.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, GRADE Working Group (2008) What is “quality of evidence” and why is it important to clinicians? BMJ 336:995–998PubMedCentralPubMedCrossRef
19.
Gluud C (2007) Hepatology may have problems with putative surrogate outcome measures. J Hepatol 46:734–742PubMedCrossRef
20.
Thwaites GE (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741–1751PubMedCrossRef
21.
Thorlund K, Engstrom J, Wetterslew J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1–115. www.​ctu.​dk/​tsa
22.
23.
Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J (2014) The thresholds for statistical and clinical significance—a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol 14:34PubMedCentralPubMedCrossRef
24.
Thorlund K, Devereaux PJ, Wetterslev J et al (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286PubMedCrossRef
25.
Wetterslev J, Thorlund K, Brok J, Gluud C (2009) Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 9:86PubMedCentralPubMedCrossRef
26.
Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926PubMedCentralPubMedCrossRef
27.
Venkatesh B, Myburgh J, Finfer S et al (2013) The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 15:83–88PubMed
28.
Hughes GS Jr (1984) Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sci 35:2319–2326PubMedCrossRef
29.
Klastersky J, Cappel R, Debusscher L (1971) Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med 284:1248–1250PubMedCrossRef
30.
Scarborough M (2007) Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 357:2441–2450PubMedCrossRef
31.
Wan MH (2011) Clinical observation on the effect of dexamethasone and Chinese herbal decoction for purgation in severe acute pancreatitis patients. Chin J Integr Med 17:141–145PubMedCrossRef
32.
Cicarelli DD, Bensenor FE, Vieira JE (2006) Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J 124:90–95PubMedCrossRef
33.
Confalonieri M, Urbino R, Potena A et al (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242–248PubMedCrossRef
34.
Thorlund K, Imberger G, Walsh M et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS One 6:e25491PubMedCentralPubMedCrossRef
35.
Bernard GR, Luce JM, Sprung CL et al (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317:1565–1570PubMedCrossRef
36.
37.
Hoffman SL (1984) Effective treatment and prevention of typhoid fever: updated. Trans Am Clin Climatol Assoc 95:52–65PubMedCentralPubMed
38.
Marik PP (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 104:389–392PubMedCrossRef
39.
Nafae R, Ragab M, Amany F, Rashed S (2013) Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 62:439–445
40.
Snijders D (2010) Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 181:975–982PubMedCrossRef
41.
Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRef
42.
Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF (1988) Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 138:62–68PubMedCrossRef
43.
44.
Sprung CL, Caralis PV, Marcial EH et al (1984) The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311:1137–1143PubMedCrossRef
45.
Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 317:659–665CrossRef
46.
Annane D, Sebille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRef
47.
Arabi YM, Aljumah A, Dabbagh O et al (2010) Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 182:1971–1977PubMedCentralPubMedCrossRef
48.
Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650PubMedCrossRef
49.
Briegel J, Forst H, Haller M et al (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732PubMedCrossRef
50.
Chawla K, Kupfer Y, Tessler S (1999) Hydrocortisone reverses refractory septic shock [abstract]. Crit Care Med 27:A33CrossRef
51.
Cicarelli DD, Vieira JE, Bensenor FE (2007) Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J 125:237–241PubMedCrossRef
52.
Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, Brett SJ (2014) The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 42:1325–1333PubMedCrossRef
53.
Hu B, Li JG, Liang H et al (2009) The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 21:529–531PubMed
54.
Kaufmann I, Briegel J, Schliephake F et al (2008) Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med 34:344–349PubMedCrossRef
55.
Mirea L, Ungureanu R, Pavelescu D, Grintescu I, Dumitrache C, Mirea D, Grintescu I (2014) Continuous administration of corticosteroids in septic shock can reduce risk of hypernatremia. Critical care (London, England) conference: 34th international symposium on intensive care and emergency medicine, Brussels, Belgium. Conference Publication, S86
56.
Meduri GU, Golden E, Umberger R (2009) Prospective double-blind randomized clinical trial on the effects of low-dose hydrocortisone infusion in patients with severe sepsis. Chest 136:45SCrossRef
57.
Oppert M, Schindler R, Husung C et al (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457–2464PubMedCrossRef
58.
Rinaldi S, Adembri C, Grechi S, De Gaudio AR (2006) Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 34:2334–2339PubMedCrossRef
59.
Ruolan H, Zhong Z, Mujuan X, Xiao C, Qiujie Q, Ling W, Xinke M (2014) Effect of Sini decoction on function of hypothalamic–pituitary–adrenal axis in patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 26:184 (in Chinese)
60.
Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124PubMedCrossRef
61.
62.
Yildiz O, Tanriverdi F, Simsek S, Aygen B, Kelestimur F (2011) The effects of moderate-dose steroid therapy in sepsis: a placebo-controlled, randomized study. J Res Med Sci 16:1410–1421PubMedCentralPubMed
Metadata
Title
Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis
Authors
M. Volbeda
J. Wetterslev
C. Gluud
J. G. Zijlstra
I. C. C. van der Horst
F. Keus
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 7/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-015-3899-6

Other articles of this Issue 7/2015

Intensive Care Medicine 7/2015 Go to the issue

From the Inside

Non-verbal communication to restore patient–provider trust

Letter

High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients

Original

Acute kidney injury after out-of-hospital cardiac arrest: risk factors and prognosis in a large cohort

Correspondence

Acute mesenteric ischemia, procalcitonin, and intensive care unit

Original

More than half the families of mobile intensive care unit patients experience inadequate communication with physicians

Conference Reports and Expert Panel

Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)